The Literature By Leonard K. Seibold, MD; Malik Y. Kahook, MD; and Jeffrey R. SooHoo, MD
What Is the Real IOP?
Laboratory studies may help us better understand our clinical dilemmas.
By Dan Eisenberg, MD
Highlights of the 2016 ARVO Annual Meeting
Select research findings presented this year.
By Sze H. Wong, MD, and Albert S. Khouri, MD
News Feature: a New Option for Uveitis
Adalimumab, a rheumatology drug, offers hope to patients with this damaging inflammatory eye disease.
By Agustin L. Gonzalez, OD
Glaucoma After Corneal Limbal Stem Cell Transplantation By Ahmad A. Aref, MD; Kavitha R. Sivaramen, MD; and Ali R. Djalilian, MD
Foundations of a Great Physician By Linda Huang, MD
Ocular Surface Disease: Impact on Glaucoma Surgical Decision Making
The preoperative planning process is more complex and requires careful attention to the unique issues at play.
By Tony Realini, MD, MPH
The Dark Side of Medication
Many systemic and topical drugs can cause or worsen dry eye disease.
By Sarah Marshall, PhD, and Robert Noecker, MD, MBA
Tear Osmolarity in a Glaucoma Practice
The role of point-of-care testing in dry eye disease and glaucoma management.
By Leslie E. O’Dell, OD
The principles and clinical significance of various technologies.
By Alice T. Epitropoulos, MD
Intense Pulsed Light for Dry Eye Disease
This procedure improves the health of the meibomian glands.
By Rolando Toyos, MD
What Every Glaucoma Doctor Should Know About DED
New technologies provide more information and better outcomes than ever before.
By Sheri Rowen, MD
Punctal Occlusion and Ocular Nutrition By Paul S. Koch, MD, and Thandeka Myeni, MD, MPH
Neurostimulation: a Novel Approach to Treating the Signs and Symptoms of Dry Eye
A device in clinical study could lead to new understanding of dry eye as a neuronal disease.
By John Berdahl, MD
Being a Doctor, Thinking Like a CEO
The merging of two mindsets requires skill, versatility, and sensitivity.
By Wolfgang Riha, MD
The Literature By Reena A. Garg, MD, and Helen Jiang, MD
Detecting and Treating Glaucoma in a Myopic Patient Without High IOP By Robert Chang, MD, and Kuldev Singh, MD, MPH
The Eyes of Africa Project
Partners bring comprehensive eye care to rural Malawi.
By William Eric Sponsel, MD
Assessing Corneal Biomechanics
The importance of these properties rests primarily with their effects on IOP measurement.
By Leon W. Herndon, MD
Evaluating Quality of Life in Glaucoma
Understand the impact of the disease to improve care.
By Felipe A. Medeiros, MD, PhD
Do We Need Perimetry?
As glaucoma advances, visual field testing provides valuable insight.
By Murray Fingeret, OD
Enhancing Visual Field Testing
Techniques to increase the value and reliability of visual fields.
By Oluwatosin Smith, MD
The Role of Optic Nerve Head Imaging
Past, present, and future.
By Anitra Turner, MD, and Anjali Bhorade, MD, MSCI
Optical Coherence Tomography as a Glaucoma Screening Tool
Does it affect glaucoma detection in the community?
By Lisa F. Rosenberg, MD, and Casey Cahill, MD
Is There Still a Role for Optic Disc Photography?
New is not necessarily better.
By George L. Spaeth, MD; Kamran Rahmatnejad, MD; and Lichuan Zeng, BSE
Fighting Side by Side By Sze H. Wong, MD
Down, But Not Out: How the AAO Has Responded to Medicare's 2016 Ophthalmology Fee Cuts
Faced with cuts to ophthalmic reimbursements, the American Academy of Ophthalmology sprang into action.
By George A. Williams, MD
The Literature By Alex S. Huang, MD, PhD, and Alan T. Begian
What Is the Real IOP?
How laboratory glaucoma studies may help us better understand this clinical dilemma.
By Nathan Radcliffe, MD
Screening the Future By Avni Shah, MD
Why I Perform Research in a Clinical Practice
Participating in clinical research provides new options for my patients and growth opportunities for my practice.
By Gregory D. Parkhurst, MD
Highlights of the AGS Annual Meeting
The latest research findings from the 26th annual meeting of the American Glaucoma Society, held March 3 to 6, 2016, in Fort Lauderdale, Florida.
By Geoffrey T. Emerick, MD
Rho Kinase/Norepinephrine Transporter Inhibition for the Treatment of Glaucoma and Ocular Hypertension
An update on the clinical development of a new class of drugs.
By Jason Bacharach, MD
Tools of the Tube Trade By Jonathan S. Myers, MD
The Literature By Andrew Garcia, MD, and Christopher C. Teng, MD
Addressing Poor Adherence By Larissa Habib, MD
Is the Grass Really Greener on the Other Side?
The pros and cons of ophthalmology business models.
By Richard A. Lehrer, MD
Dealing With Reimbursement Cuts
Two surgeons share their strategies.
By Paul F. Palmberg, MD, PhD, and Jeffrey A. Kammer, MD